Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with diabetes and established cardiovascular disease [1]. It is important to note that Ozempic is not specifically indicated to affect meal portions; rather, it affects appetite regulation and blood sugar levels.

Ozempic works by mimicking the functions of the body's natural GLP-1 hormone, which plays a crucial role in regulating blood sugar levels and appetite [2]. By binding to GLP-1 receptors, Ozempic helps to slow down gastric emptying, leading to a feeling of fullness and reduced appetite [3]. Consequently, patients may find themselves consuming smaller meal portions naturally due to the reduced appetite and feeling of fullness.

In summary, Ozempic does not directly affect meal portions but rather influences appetite regulation, leading to a possible reduction in meal portions. It is essential to consult with healthcare professionals for personalized advice and recommendations regarding meal portions and diabetes management.

Sources:

[1] U.S. Food and Drug Administration. (2017). Ozempic (semaglutide) injection, for subcutaneous use. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ozempic-semaglutide-injection-subcutaneous-use>

[2] National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Ozempic. <https://www.niddk.nih.gov/health-information/diabetes/overview/drug-treatment/ozempic>

[3] Drugs.com. (2021). Ozempic. <https://www.drugs.com/ozempic.html>

[4] DrugPatentWatch.com. (2021). Semaglutide. <https://www.drugpatentwatch.com/drugs/semaglutide>